Tarsus Pharmaceuticals
TARS
73.61
-0.50
-0.67%
Tarsus Pharmaceuticals
US · TARS
#2389 by market cap
Listed 2020
73.61
-0.50
-0.67%
Live - 5344 symbols - heartbeat 132s ago
· 2026-10-08 07:01
Pre-market
73.46
-0.20%
After-hours
73.61
0.00%
- Market cap
- 3.44B
- P/E (TTM)i
- -68.79
- P/Bi
- 9.93
- EPSi
- -1.59
- Div yieldi
- 0.00%
- 52W posi
- 52%
Reader sentiment
Are you bullish or bearish on TARS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- Total institutional ownership fell 2.0 percentage points.
Institutional ownership
- Held by institutions
- 111.44% -2.04pp
- Institutions
- 315
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund58.89%
Hedge Fund27.09%
VC/PE Fund11.05%
Public Company10.00%
Private Company3.25%
Individual/Insider3.06%
Government Pension Fund0.82%
Insurance Company0.29%
Top holders as of 2026-06-30
BlackRock
8.79% · 3.86M sh
Deep Track Capital, LP
8.36% · 3.67M sh
RTW Investments, LP
7.65% · 3.36M sh
Janus Henderson Group plc
6.40% · 2.81M sh
Paradigm Biocapital Advisors LP
6.33% · 2.78M sh
Vanguard Capital Management, LLC
4.74% · 2.08M sh
Morgan Stanley
3.99% · 1.75M sh
Jennison Associates LLC
3.79% · 1.66M sh
Tang Capital Management, LLC
3.57% · 1.57M sh
Millennium Management LLC
3.25% · 1.43M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 24 buys · 26 sells
| Name | Role | Stake |
|---|---|---|
| Bobak Azamian | Chairperson & CEO | 1.96% |
| William Link | Independent Director | 0.22% |
| Seshadri Neervannan | Chief Operating Officer | 0.18% |
| Bryan Wahl | General Counsel | 0.15% |
| Aziz Mottiwala | Chief Commercial Officer | 0.14% |
| Jeffrey S. Farrow | CFO & Chief Strategy Officer | 0.13% |
| Dianne Whitfield | Chief Human Resources Officer | 0.08% |
| Andrew Goldberg | Independent Director | 0.04% |
| Wendy Yarno | Lead Independent Director | 0.04% |
| Elizabeth Yeu-Lin | Chief Medical Advisor & Director | 0.04% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-14 | William Link | Independent Director | Automatic Disposition | -12,299 | $78.33–80.01 |
| 2026-09-14 | William Link | Independent Director | Derivative Exercise and Sale | -201 | $78.33 |
| 2026-09-14 | David E. Pyott | Independent Director | Derivative Exercise and Retained | +201 | -- |
| 2026-09-14 | Wendy Yarno | Lead Independent Director | Derivative Exercise and Retained | +302 | -- |
| 2026-09-03 | Bobak Azamian | Chairperson & CEO | Automatic Disposition | -10,000 | $90.27–91.27 |
| 2026-09-03 | Seshadri Neervannan | Chief Operating Officer | Open Market Disposition | -4,564 | $85.00 |
| 2026-09-03 | Elizabeth Yeu-Lin | Chief Medical Advisor & Director | Automatic Disposition | -13,953 | $85.00–90.00 |
| 2026-09-01 | Bobak Azamian | Chairperson & CEO | Automatic Disposition | -10,000 | $80.06 |
| 2026-09-01 | Aziz Mottiwala | Chief Commercial Officer | Intent to Sell (Form 144) | -8,000 | $81.80 |
| 2026-09-01 | Elizabeth Yeu-Lin | Chief Medical Advisor & Director | Automatic Disposition | -11,578 | $73.86–80.00 |
| 2026-09-01 | Elizabeth Yeu-Lin | Chief Medical Advisor & Director | Intent to Sell (Form 144) | -5,387 | $80.00 |
| 2026-09-01 | Elizabeth Yeu-Lin | Chief Medical Advisor & Director | Intent to Sell (Form 144) | -1,590 | $80.00 |
| 2026-08-31 | Aziz Mottiwala | Chief Commercial Officer | Intent to Sell (Form 144) | -77,698 | $73.96 |
| 2026-08-31 | Elizabeth Yeu-Lin | Chief Medical Advisor & Director | Intent to Sell (Form 144) | -4,601 | $73.86 |
| 2026-08-24 | Aziz Mottiwala | Chief Commercial Officer | Intent to Sell (Form 144) | -81,332 | $71.85 |
| 2026-08-18 | Aziz Mottiwala | Chief Commercial Officer | Intent to Sell (Form 144) | -53,043 | $72.00 |
| 2026-06-24 | William Link | Independent Director | Other Derivative Acquisition | +3,223 | -- |
| 2026-06-24 | William Link | Independent Director | Other Derivative Acquisition | +3,837 | $64.34 |
| 2026-06-24 | David E. Pyott | Independent Director | Other Derivative Acquisition | +3,223 | -- |
| 2026-06-24 | David E. Pyott | Independent Director | Other Derivative Acquisition | +3,837 | $64.34 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:01:30 · For reference only, not investment advice and not tailored to your situation.